# An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

> **NCT07102459** · PHASE2 · COMPLETED · sponsor: **Latigo Biotherapeutics** · enrollment: 343 (actual)

## Conditions studied

- Acute Pain
- Postoperative Pain Control

## Interventions

- **DRUG:** Experimental: LTG-001 High Dose
- **DRUG:** Experimental: LTG-001 Low Dose
- **DRUG:** Active Comparator: HB/APAP
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT07102459
- **Lead sponsor:** Latigo Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-24
- **Primary completion:** 2026-01-07
- **Final completion:** 2026-01-07
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07102459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07102459, "An Efficacy and Safety Study of LTG-001 Following Abdominoplasty". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07102459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*